The study compared the efficacy of endoscopic sleeve gastroplasty versus lifestyle interventions (behavioural therapy, diet and exercise) with or without pharmacotherapy in patients with class I and II obesity.
This Ratified PICO Confirmation from February 2019 outlines the Medical Services Advisory Committee (MSAC) assessment framework for Application 1555, which proposes endoscopic sleeve gastroplasty for patients aged 18 years or over with BMI 30.0–39.9 kg/m² who have major medical comorbidities and have failed first- and second-line treatments. The document defines the patient population, intervention (endoscopic sleeve gastroplasty plus lifestyle interventions), comparators (lifestyle interventions alone for BMI 30.0–34.9; sleeve gastrectomy or laparoscopic adjustable gastric banding plus lifestyle for BMI 35.0–39.9), and outcomes including safety, efficacy, healthcare resources, and cost-effectiveness.
The document provides background on obesity prevalence in Australia, noting 4.9 million Australians classified as obese (4.3 million in class I or II), common comorbidities (arthritis 27.7%, hypertension 24.5%, mental health problems 22.6%, diabetes 12.8%), and current chronic disease model of care. Treatment failure is defined as inability to achieve minimum 5% weight loss within 3 months. The rationale considers clinical need for durable weight loss beyond short-term lifestyle interventions.
Patients aged 18 years or over with BMI 30.0–39.9 kg/m² who have one or more major medical comorbidities and have failed first- and second-line treatment options.
Treatment failure is defined as an inability to achieve a minimum of 5 per cent weight loss within 3 months.